Antibe Therapeutics (Antibe Therapeutics) PB Ratio : 0.59 (As of Apr. 25, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Antibe Therapeutics's share price is $0.2156. Antibe Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.37. Hence, Antibe Therapeutics's PB Ratio of today is 0.59.

The historical rank and industry rank for Antibe Therapeutics's PB Ratio or its related term are showing as below:

ATBPF' s PB Ratio Range Over the Past 10 Years
Min: 0.24 Med: 4.28 Max: 59.69
Current: 0.6

During the past 12 years, Antibe Therapeutics's highest PB Ratio was 59.69. The lowest was 0.24. And the median was 4.28.

ATBPF's PB Ratio is ranked better than
89.47% of 1311 companies
in the Biotechnology industry
Industry Median: 2.37 vs ATBPF: 0.60

During the past 12 months, Antibe Therapeutics's average Book Value Per Share Growth Rate was -40.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 80.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 29.90% per year.

During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Antibe Therapeutics was 80.80% per year. The lowest was -30.90% per year. And the median was 39.80% per year.

Back to Basics: PB Ratio

Antibe Therapeutics PB Ratio Historical Data

The historical data trend for Antibe Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics PB Ratio Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

PB Ratio

Get a 7-Day Free Trial

9.17

45.13

4.63

0.74

0.79

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
PB Ratio	Get a 7-Day Free Trial															0.53	0.79	0.70	0.86	1.86

Competitive Comparison of Antibe Therapeutics's PB Ratio

For the Biotechnology subindustry, Antibe Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's PB Ratio falls into.

Antibe Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Antibe Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio	=	Share Price	/	Book Value per Share (Q: Dec. 2023)
	=	0.2156	/	0.367
	=	0.59

It can also be calculated from the numbers for the whole company:

PB Ratio

Market Cap

(Total Stockholders Equity

Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Antibe Therapeutics (OTCPK:ATBPF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Antibe Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (Antibe Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » PB Ratio

Comparable Companies

Traded in Other Exchanges

ATE:Canada

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.